In many cardiovascular diseases, elevated plasma CX3CL1/fractalkine concentrations increased platelet activation and the formation of platelet–monocyte complexes, eventually resulting in the promotion of atherosclerosis. This evidence concerns the gene CX3CL1 and atherosclerosis.